Berkowitz R, Kabawat S, Lazarus H, Colvin R, Knapp R, Bast R C
Am J Obstet Gynecol. 1983 Jul 15;146(6):607-12. doi: 10.1016/0002-9378(83)90999-7.
An ovarian carcinoma cell line (OVCA 432) and a B-lymphocyte line (LAZ 446) were established from the same donor. A heteroantiserum (D-100) was prepared in rabbits against OVCA 432 and absorbed with LAZ 446, human AB erythrocytes, and the CX-1 colorectal cell line. After absorption, D-100 reacted by indirect immunofluorescence with six of six epithelial ovarian carcinoma cell lines and cryostat sections of 18 of 18 epithelial ovarian tumors but bound to zero of 12 nonovarian tumor cell lines. Despite a lack of reactivity with nonovarian tumor cell lines, D-100 reacted with epithelial components of normal ovary, fallopian tube, endometrium, endocervix, breast, colon, and epididymis. A murine monoclonal antibody (OC 133) was also raised against OVCA 432 and selected for lack of reactivity with the autologous B-lymphocyte line LAZ 446. OC 133 reacted with six of six ovarian carcinoma cell lines and cryostat sections of seven of 19 ovarian tumors, but it also reacted with five of five nonovarian tumor cell lines. Of 12 normal tissues examined, OC 133 reacted with endometrium and endocervix only. Whereas D-100 bound to serous, mucinous, endometrioid, and clear cell ovarian neoplasms, OC 133 bound only to serous tumors. In developing monoclonal reagents, cell lines may provide a useful source of antigen, but promising antibodies should be screened for reactivity with sections of normal and malignant human tissues.
一种卵巢癌细胞系(OVCA 432)和一种B淋巴细胞系(LAZ 446)取自同一供体。用兔制备了针对OVCA 432的异种抗血清(D - 100),并用LAZ 446、人AB红细胞和CX - 1结肠癌细胞系进行吸收处理。吸收后,D - 100通过间接免疫荧光法与6种上皮性卵巢癌细胞系中的6种以及18例上皮性卵巢肿瘤的冷冻切片发生反应,但与12种非卵巢肿瘤细胞系中的0种发生结合。尽管D - 100与非卵巢肿瘤细胞系无反应,但它与正常卵巢、输卵管、子宫内膜、子宫颈内膜、乳腺、结肠和附睾的上皮成分发生反应。还制备了一种针对OVCA 432的鼠单克隆抗体(OC 133),并筛选出与自体B淋巴细胞系LAZ 446无反应的抗体。OC 133与6种卵巢癌细胞系中的6种以及19例卵巢肿瘤中的7例冷冻切片发生反应,但它也与5种非卵巢肿瘤细胞系中的5种发生反应。在所检查的12种正常组织中,OC 133仅与子宫内膜和子宫颈内膜发生反应。D - 100与浆液性、黏液性、子宫内膜样和透明细胞性卵巢肿瘤发生结合,而OC 133仅与浆液性肿瘤发生结合。在开发单克隆试剂时,细胞系可能是有用的抗原来源,但对于有前景的抗体,应筛选其与正常和恶性人体组织切片的反应性。